Pharmaceuticals Singapore

Singapore Gene Editing Market Analysis, 2024–2034

Singapore Gene Editing Market Industry Trends and Forecast to 2034: Segmented by (Technology, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Singapore · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $8.7 Mn Estimated value
Estimate 2025 $10.3 Mn 0.1% of the global market
Projected 2034 $47.2 Mn 360.7% Adds $37.0 Mn over 9 forecast years
CAGR 2025–2034 18.5% Faster than 82% of 180 Pharmaceuticals markets here
Key players 6 Companies profiled
  • Singapore is 0.13% of the global market.
  • In APAC, the largest is China at $546.4 Mn.
  • Fastest growing: India at 21% a year.
  • Singapore ranks 9th of 10 by size in APAC.

Market size projection

Singapore

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$37.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Gene Editing Market market size by year, Singapore
YearMarket sizeChange that yearSince 2025
2024 (estimate) $8.7 Mn — —
2025 (base) $10.3 Mn +$1.6 Mn —
2026 (forecast) $12.1 Mn +$1.9 Mn +18.5%
2027 (forecast) $14.4 Mn +$2.2 Mn +40.4%
2028 (forecast) $17.1 Mn +$2.7 Mn +66.4%
2029 (forecast) $20.2 Mn +$3.2 Mn +97.2%
2030 (forecast) $24.0 Mn +$3.7 Mn +133.7%
2031 (forecast) $28.4 Mn +$4.4 Mn +176.9%
2032 (forecast) $33.6 Mn +$5.3 Mn +228.1%
2033 (forecast) $39.9 Mn +$6.2 Mn +288.8%
2034 (forecast) $47.2 Mn +$7.4 Mn +360.7%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $7.80 Bn
  2. North America $3.56 Bn
  3. US $3.01 Bn
  4. APAC $1.74 Bn
  5. Europe $1.41 Bn
  6. Canada $615.2 Mn
  7. China $546.4 Mn
  8. Japan $424.3 Mn
  9. Latin America $405.9 Mn
  10. Middle East $353.7 Mn
  11. Germany $296.6 Mn
  12. France $208.2 Mn
  13. Brazil $191.9 Mn
  14. UK $178.9 Mn
  15. Italy $179.8 Mn
  16. Spain $153.9 Mn
  17. Ecuador $150.2 Mn
  18. Saudi Arabia $149.7 Mn
  19. Africa $135.9 Mn
  20. Mexico $131.4 Mn
  21. India $128.5 Mn
  22. Australia $96.8 Mn
  23. Russia $83.5 Mn
  24. New Zealand $83.5 Mn
  25. South Africa $53.6 Mn
  26. UAE $40.2 Mn
  27. Egypt $23.3 Mn
  28. Philippines $14.9 Mn
  29. Hong Kong $13.7 Mn
  30. Malaysia $11.8 Mn
  31. Singapore (this report) $10.3 Mn
  32. Thailand $9.2 Mn
  33. Kenya $5.2 Mn

The Singapore Gene Editing Market Analysis Executive Summary

Gene editing tools such as CRISPR, base editing and prime editing change DNA inside cells to fix or switch off faulty genes.

Key segments of the gene Editing market include technology (CRISPR-Cas9, Base Editing and Prime Editing) and application (Therapeutics, Research and Agriculture).

Singapore Gene Editing Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Editing market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Editing market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Editing market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Gene Editing Market in Singapore

The gene Editing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Gene Editing Market in Singapore

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Editing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Singapore.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Gene Editing right now, from free public sources.

Clinical trials

2 active trials in Singapore

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. CRISPR Therapeutics 6 active trials on ClinicalTrials.gov (opens in a new tab)
  2. HuidaGene Therapeutics Co., Ltd. 4 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Intellia Therapeutics 2 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Editas Medicine 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Caribou Biosciences 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 12,644 papers since 2021 (worldwide)

  1. Application of AI-designed OpenCRISPR-1 for highly efficient gene editing in soybean (Glycine max L.) and Nicotiana benthamiana. Transgenic research, 2026
  2. Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1. Journal of human immunity, 2026
  3. Therapeutic Targeting of Oxidative Stress in Hematopoietic Stem Cells: Current Strategies and Future Directions. Stem cells international, 2026
  4. Large Insertion Using Template-Jumping Prime Editing. Methods in molecular biology (Clifton, N.J.), 2026
  5. All-in-One Prime Editing System for Efficient Generation and Isolation of Single Edited hiPSC Clones. Methods in molecular biology (Clifton, N.J.), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Gene Editing in context

Singapore compared

  • Health spending per person: 3,922 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.83 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.2% of people (2025). World: 10.4% of people (2025). 7th highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on Gene Editing are running in Singapore?
2 studies are recruiting, active or about to start in Singapore.[4]
How much research is published on Gene Editing?
PubMed lists 12,644 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Gene Editing in Singapore? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Singapore

See all
Same topic, other categories

Related on cell and gene therapy and genomics

See the topic